Date: 2013-09-06
Type of information: Grant
Company: Canbex Therapeutics (UK)
Investors: Biomedical Catalyst Fund (UK)
Amount: £1.25 million (€ 1.48 million)
Funding type: grant
Planned used: The grant will be used to support the development of VSN16R for the treatment of spasticity in multiple sclerosis.
Others: * On September 6, 2013, Canbex Therapeutics has announced that it has secured a grant of £1.25M to further support the development of VSN16R. The company has also recently completed a £2.1m financing round to contribute to the development of its lead candidate VSN16R for the treatment of spasticity in multiple sclerosis.
Keith Powell , chairman of Canbex said “ The grant enables us to deliver a very high quality of program in the first human trials, starting next month, and we anticipate will deliver a phase 2 ready project within a year. The grant will also enable supporting studies in the laboratories of Prof David Baker at Queen Mary, University of London and Prof David Selwood, the inventor of VSN16R at UCL.”.
Therapeutic area: Neurodegenerative diseases
